Clinical trial
Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic…
NCT00087334 · Roswell Park Cancer Institute, Other · Terminated
Key facts
| NCT number | NCT00087334 |
|---|---|
| Title | Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer |
| Official title | A Phase I/II Study of Capecitabine (XELODA®, Roche) Plus Oxaliplatin (Eloxatin®, Sanofi) Plus ZD 1893 (IRESSA®) in the Treatment of Metastatic Colorectal Cancer |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | capecitabine, gefitinib, oxaliplatin |
| Enrollment | 10 |
| Start date | Jan 1, 2004 |
| Primary completion | Nov 1, 2005 |
| First posted | Jul 12, 2004 |
| Last update posted | Feb 1, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: